Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cord blood + antithymocyte globulin + cyclosporine
- Development stage
- Unknown
- Lead developer
- Shanghai General Hospital
- Modality
- Cell Therapies, Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This therapeutic intervention is a combination therapy protocol for the treatment of severe aplastic anemia (SAA). It involves the administration of standard immunosuppressive therapy (IST) consisting of antithymocyte globulin (ATG) and cyclosporine A (CsA), supplemented by a single unit of HLA-matched umbilical cord blood transfusion. The antithymocyte globulin and cyclosporine work to suppress the T-cell-mediated autoimmune destruction of the bone marrow, while the cord blood transfusion provides transient hematopoietic support. The cord blood delivers early hematopoietic progenitor cells that can temporarily survive and proliferate, secreting hematopoietic stimulating factors that help patients overcome agranulocytosis and shorten the time to hematopoietic reconstitution. This protocol is being investigated by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine in Phase 4 clinical trials.
- Other names
- cord blood transfusion combined with immunosuppressive therapycord blood transfusion and ISTcord blood-Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine-severe aplastic anemia
02
Targets
CN (Calcineurin)
Beyond the preview
Go deeper on cord blood + antithymocyte globulin + cyclosporine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cord blood + antithymocyte globulin + cyclosporine.